Skip to content
Menu

Dermata Therapeutics, Inc. DRMA

Full chart Compare
Set alert

Price alert · DRMA

All alert types
0.51 USD -0.02 (-4.23%)

Regular-session close

0.51 0.00 +0.10%

After hours · Nov 20, 4:00 PM ET

0.5004 Day range 0.547
0.5004 52-week range 4.66
YTD
-78.04%
1 year
-79.62%

5D -0.1698 (-22.95%)

0.60000.7000WedThuFriMonTue0.5701
Market cap
2.51M
EPS (ttm)
-3.28
Shares out
2.04M
Forward P/E
-0.32
YTD return
-78.04%
1-year return
-79.62%
50-day average
1.27
200-day average
2.84
Volume
26.59K
Avg volume
2.79M
Open
0.5319
Previous close
0.532
Day's range
0.5004 – 0.547
52-week range
0.5004 – 4.66
Beta
0.79
Price target
6.00 (+1077.6%)

Key statistics

Enterprise value
-3.38M
Price / book
0.05
Free cash flow
-4.24M
Total cash
4.95M
Return on equity
-173.01%
Short % of float
6.28%

Fundamental scorecard

1 of 25 checks passed on DRMA’s reported financials

ValueGrowthProfitabilityHealthDividend

1of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health No data
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
DRMA Revenue — quarterly 74.14K
DRMA Net income — quarterly -2.82M
DRMA EPS — quarterly -0.55

Earnings

DRMA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 20240.00-2.04——
Aug 7, 2024Jun 1, 20240.00-4.18——
May 15, 2024Mar 1, 20240.00-7.05——
Mar 21, 2024Dec 1, 20230.00-3.15——
Nov 9, 2023Sep 1, 20230.00-8.10——
Aug 10, 2023Jun 1, 20230.00-9.45——

Upgrades / downgrades

DRMA analyst upgrades and downgrades
DateFirmActionFromTo
Aug 21, 2024Maxim GroupmainBuyBuy
Mar 23, 2023Maxim Groupmain—Buy

About Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on DRMA — it syncs with the Stock Master app.

Institution ownership

DRMA institution ownership
Holder% heldSharesValueReported
Tower Research Capital LLC (TRC)0.14%2,8923.56KSep 29, 2024
Wells Fargo & Company0.10%2,0452.52KSep 29, 2024
UBS Group AG0.07%1,4971.84KSep 29, 2024
Bank of America Corporation0.00%1012Sep 29, 2024

Fund ownership

DRMA fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.32%6,5828.10KOct 30, 2024
Fidelity Series Total Market Index Fund0.09%1,8262.25KOct 30, 2024